The SENS Research Foundation is a non-profit organization that does research programs and public relations work for the application of regenerative medicine to aging. It was founded in 2009, located in Mountain View, California, USA. The organization publishes its reports annually. Before the foundation was founded in March 2009, the SENS research program was mainly pursued by the Methuselah Foundation, co-founded by Aubrey de Grey and David Gobel. When the SENS rejuvenation approach was announced in the 2000s, while some biogerontologists supported the SENS program, many contended that the ultimate goals of de Grey's programme were too speculative given the state of technology and referred to it as "fantasy rather than science". By the mid-2010s, the rejuvenation approach gained traction with multiple startup companies created from SENS research findings. In 2021 Michael Greve pledged another €300 million for rejuvenation biotechnology startup companies. In 2021, Underdog Pharmaceuticals, a startup company spun out from a research program at SENS Research Foundation, was awarded an Innovation Passport from the United Kingdom Medicines and Healthcare products Regulatory Agency, which intends to streamline the approval program of promising therapies. In August 2021, Aubrey de Grey was suspended from the foundation. The CEO of the SENS Research Foundation, Jim O’Neill left in the preceding July, at the same time de Grey was suspended. More information...
According to PR-model, sens.org is ranked 38,462nd in multilingual Wikipedia, in particular this website is ranked 25,485th in English Wikipedia.
The website is placed before legistar.com and after ganglandnews.com in the BestRef global ranking of the most important sources of Wikipedia.
